PT  - JOURNAL ARTICLE
AU  - Flisiak, Robert
AU  - Jaroszewicz, Jerzy
AU  - Rogalska, Magdalena
AU  - Łapiński, Tadeusz
AU  - Berkan-Kawińska, Aleksandra
AU  - Bolewska, Beata
AU  - Tudrujek-Zdunek, Magdalena
AU  - Kozielewicz, Dorota
AU  - Rorat, Marta
AU  - Leszczyński, Piotr
AU  - Kłos, Krzysztof
AU  - Kowalska, Justyna
AU  - Pabjan, Paweł
AU  - Piekarska, Anna
AU  - Mozer-Lisewska, Iwona
AU  - Tomasiewicz, Krzysztof
AU  - Pawłowska, Małgorzata
AU  - Simon, Krzysztof
AU  - Polańska, Joanna
AU  - Zarębska-Michaluk, Dorota
TI  - Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis
AID  - 10.1101/2021.01.28.21249932
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.28.21249932
4099  - http://medrxiv.org/content/early/2021/02/01/2021.01.28.21249932.short
4100  - http://medrxiv.org/content/early/2021/02/01/2021.01.28.21249932.full
AB  - Background Despite the direct viral activity, the pathogenesis of coronavirus disease 2019 (COVID-19) includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore tocilizumab (TCZ), a monoclonal antibody against IL-6 receptors, became considered as a possible therapeutic option.Methods Patients were selected from the SARSTer national database, which included 2332 individuals with COVID-19 and the current study included 825 adult patients with moderate to severe course. The retrospective analysis was performed in 170 patients treated with TCZ and 655 without this medication or any other anti-cytokine therapy. The end-points of treatment effectiveness were a rate of death, need for mechanical ventilation, and clinical improvement.Results Patients treated with TCZ were balanced compared to non-TCZ regarding gender, age, BMI, and prevalence of coexisting conditions. The reduced death rate was demonstrated in patients treated with TCZ and baseline IL-6 >100 pg/ml (hazard ratio [HR]: 0.27, 95% confidence interval [CI]:0.10-0.78), or those needing oxygen supplementations who worsened within 7 days of hospitalization (HR: 0.38, 95% CI:0.16-0.88). The best effectiveness of TCZ was achieved in patients with a combination of baseline IL-6>100 pg/ml and either SpO2≤90% (HR for death, mechanical ventilation, and clinical improvement after 21 or 28 days: 0.07, 0.14, 5.53, 5.18 respectively) or requiring oxygen supplementation (HR for death and clinical improvement after 21 or 28 days, 0.18, 2.66, 2.85 respectively).Conclusions Tocilizumab administered for COVID-19 in patients with a baseline concentration of IL-6>100 pg/ml is associated with reduced mortality and faster clinical improvement, particularly if there is a need for oxygen supplementation due to SpO2≤90%.Competing Interest StatementRF reports grants from Abbvie, Gilead, Merck, personal fees from Gilead, Abbvie, Merck, Roche, and non-financial support from Abbvie, Gilead, and Merck outside the submitted work. DZM, PP reports personal fees from Gilead and Abbvie, outside the submitted work. JJ reports personal fees from Gilead, Abbvie, Bausch Health, Merck, Promed, Roche, and non-financial support from Abbvie, Gilead, and Merck outside the submitted work. KS reports personal fees from Gilead, Abbvie, Merck, outside the submitted work KT reports personal fees from Gilead, Abbvie, Merck, Promed, Roche, and non-financial support from Abbvie, Gilead, and Merck outside the submitted work. JK reports personal fees from Gilead, Merck, ViiV, Janssen outside the submitted work. IML reports personal fees from Gilead, Abbvie and Pfizer ABK, JP, BB, KK, MP, AP, DK, MTZ, CI, MRog, MRor declare no competing interests. Funding StatementSARSTer study is supported by the Polish Association of Epidemiologists and Infectiologists and Medica Research AgencyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received the approval of the Ethics Committee of the Medical University of Białystok. Local ethics committees approved use of tocilizumab as an experimental therapyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata will be available upon request from the first/corresponding author